Goal Statement
The goal of this educational activity is to improve learners’ knowledge, competence, and performance managing advanced therapy for patients with moderate to severe atopic dermatitis.

Target Audience
This education is intended for dermatologists, allergist/immunologists, and nurse practitioners (NPs) and physician associates (PAs) practicing in dermatology and allergy who manage patients with moderate to severe atopic dermatitis.

Learning Objectives
Upon completion of this activity, participants should be able to:

• Understand the pathophysiologic contributions of IL-13 in promoting the clinical manifestations of moderate to severe AD

• Evaluate available evidence and current guidelines to differentiate advanced therapies targeting IL-13 in moderate to severe AD

• Assess patient candidacy for advanced biologic therapies targeting IL-13 in moderate to severe AD

Agenda:

• Introduction
• Exploring the Role of IL-13 in Atopic Dermatitis
• Mastering the Evidence for IL-13 Inhibition in Moderate to Severe Atopic Dermatitis
• IL-13 Inhibitors in Practice: Patient Candidacy and Treatment Advancement Strategies
• Key Clinical Takeaways, Q&A